Recent Updates
Recently added Catalysts
KAPA Positive Sentiment

Kairos Pharma Reports Positive, Statistically Significant Interim Efficacy Data from Phase 2 Trial of ENV-105 in Metastatic Prostate Cancer

Tuesday, October 6, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Kairos Pharma has announced positive interim efficacy data from its Phase 2 trial of ENV-105 in combination with apalutamide for treating metastatic castration-resistant prostate cancer. The interim analysis revealed a statistically significant improvement in progression-free survival among patients. This data suggests potential benefits of the treatment in addressing drug resistance in cancer.

Market Sentiment Analysis

POSITIVE FACTORS

  • Positive interim efficacy data reported.
  • Statistically significant improvement in progression-free survival.
  • Combination therapy shows promise for metastatic prostate cancer.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~6 mo
Medium dilution risk
Lead asset
Carotuximab
Phase 2 · Castration-resistant Prostate Cancer

Full Press Release Details

LOS ANGELES--(BUSINESS WIRE)---- $KAPA--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company addressing drug resistance in cancer, today announced positive interim efficacy data from its ongoing Phase 2 clinical trial evaluating ENV-105 (carotuximab) in combination with apalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC). The interim analysis demonstrated a statistically significant difference in progression-free survival (PFS) between all

Frequently Asked Questions

What is ENV-105?

ENV-105, also known as carotuximab, is a treatment being evaluated for metastatic prostate cancer.

What were the results of the Phase 2 trial?

The Phase 2 trial showed statistically significant improvement in progression-free survival.

Who conducted the Phase 2 trial?

The trial was conducted by Kairos Pharma, Ltd.

What type of cancer is being targeted?

The trial targets metastatic castration-resistant prostate cancer (mCRPC).

ShareAdd on Google
Tags: KAPA Kairos Pharma ENV-105 prostate cancer mCRPC clinical trial
Last updated: Oct 6, 2026

Biotech snapshot

Cash runway
$3M liquidity · $0M/mo burn
~6 mo
Medium dilution risk
Lead asset
CarotuximabPhase 2
Castration-resistant Prostate Cancer →